氟卡尼预防卵圆孔未闭封堵术后房性心律失常:AFLOAT随机临床试验
AFLOAT试验将186例卵圆孔未闭封堵术后患者随机分为氟卡尼治疗3个月、6个月或标准治疗组,用植入式心脏监测器记录房性心律失常。6个月内28.5%患者发生房性心律失常,86.8%集中在术后第一个月;氟卡尼未能预防房性心律失常。
要点
- 封堵术后6个月内28.5%患者发生≥30秒房性心律失常,多在第一月。
- 氟卡尼治疗至少3个月与标准治疗相比,主要终点风险差1.4%(95%CI -12.9%至13.8%),无统计学意义。
- 6个月与3个月氟卡尼及标准治疗相比,次要终点风险差分别为-2.9%和-1.6%,均无统计学意义。
核心结论
- 成功卵圆孔未闭封堵术后6个月内28.5%患者发生≥30秒房性心律失常,多集中在术后第一个月,氟卡尼未能预防。
研究设计与样本
- AFLOAT为前瞻性、多中心、随机、开放标签、盲法终点评估的优效性试验(PROBE设计),共纳入186例患者,平均年龄54岁,68.8%为男性。
主要发现
- 6个月随访期间53例(28.5%)发生≥30秒房性心律失常,其中86.8%发生在封堵术后第一个月。
- 主要终点在氟卡尼至少3个月组为33/123(26.8%),标准治疗组为16/63(25.4%),风险差1.4%(95%CI -12.9%至13.8%),无统计学意义。
- 次要终点在氟卡尼6个月组为3/60(5.0%)、氟卡尼3个月组为4/63(6.3%)、标准治疗组为5/63(7.9%),风险差分别为-2.9%(95%CI -12.7%至6.9%)和-1.6%(95%CI -11.8%至8.6%)。
关键数值与推荐
- 氟卡尼用法为150 mg每日一次缓释剂型,分别持续3个月或6个月。
- 主要终点为封堵术后3个月内植入式心脏监测器记录的至少1次≥30秒房性心律失常。
- 次要终点为封堵术后3至6个月期间植入式心脏监测器记录的至少1次≥30秒房性心律失常。
临床怎么用
- 卵圆孔未闭封堵术后应关注早期房性心律失常,尤其术后第一个月。
- 不推荐常规使用氟卡尼预防封堵术后房性心律失常。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The real incidence of atrial arrhythmia (AA) after patent foramen ovale (PFO) closure and whether this complication can be prevented remain unknown. We assessed whether flecainide is effective to prevent AA during the first 3 months after PFO closure, and whether 6 months of treatment with flecainide is more effective than 3 months to prevent AA after PFO closure. METHODS: AFLOAT (Assessment of Flecainide to Lower the Patent Foramen Ovale Closure Risk of Atrial Fibrillation or Tachycardia Trial) is a prospective, multicentre, randomized, open-label, superiority trial with a blind evaluation of all the end points (PROBE [Prospective Randomized Open, Blinded End Point] design). Patients were randomized in a 1:1:1 ratio after PFO closure to receive flecainide (150 mg once daily in a sustained-release dose) for 3 months, flecainide (150 mg once daily in a sustained-release dose) for 6 months, or no additional treatment (standard of care) for 6 months. The primary end point was the percentage of patients with at least 1 episode of AA (≥30 seconds) recorded within 3 months after PFO closure on long-term monitoring with an insertable cardiac monitor. The secondary end point was the percentage of patients with at least 1 episode of AA (≥30 seconds) recorded with insertable cardiac monitor during the 3- to 6-month period after PFO closure. RESULTS: A total of 186 patients were included (mean age, 54 years; 68.8% men) and AA (≥30 seconds) occurred in 53 patients (28.5%) during the 6-month follow-up; 86.8% of these AA events occurred in the first month after PFO closure. The primary outcome occurred in 33 of 123 (26.8%) and 16 of 63 (25.4%) patients receiving flecainide for at least 3 months or standard of care, respectively (risk difference, 1.4% [95% CI, -12.9% to 13.8%]; NS). The secondary end point occurred in 3 of 60 (5.0%), 4 of 63 (6.3%), and 5 of 63 (7.9%) patients receiving flecainide for 6 months, for 3 months, or standard of care, respectively (risk difference, -2.9% [95% CI, -12.7% to 6.9%], and risk difference, -1.6% [95% CI, -11.8% to 8.6%], respectively). CONCLUSIONS: In the first 6 months after successful PFO closure, AA (≥30 seconds) occurred in 28.5% of cases, mostly in the first month after the procedure. Flecainide did not prevent AA after PFO closure. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05213104.
引用
- Hauguel-Moreau M, Guedeney P, Dauphin C, et al. Flecainide to Prevent Atrial Arrhythmia After Patent Foramen Ovale Closure: AFLOAT Study, A Randomized Clinical Trial. Circulation. 2024. PMID: 39222035. doi:10.1161/CIRCULATIONAHA.124.071186
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。